The express originated from the thinking in the university dormitory, and the US$135 million helped the "gradual freezing syndrome" in the final sprint of new drug research

▎Editor of WuXi AppTec's content team On July 20, 2021, Amylyx Pharmaceuticals announced the completion of a US$135 million Series C financing
.

The funds obtained in this round of financing will be used to support the clinical development and marketing plan of its main drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), AMX0035, and to further develop potential therapies for other neurodegenerative diseases
.

It is worth mentioning that the co-founders of this company, Mr.
Joshua Cohen and Mr.
Justin Klee, were only undergraduates in their early 20s when they founded Amylyx
.

AMX0035 originated from their thinking in the university dormitory
.

AMX0035 is a new type of small molecule combination drug that combines two active substances with complementary activities-sodium phenylbutyrate (PB) and taurine glycol (TURSO) into an oral compound preparation
.

Preclinical trials have shown that the synergistic effect of the combination of these two drugs can reduce the death of nerve cells due to oxidative stress by 90%
.

The drug also targets neuronal degeneration caused by the dysfunction of endoplasmic reticulum and mitochondria in ALS and other neurodegenerative diseases.
It can reduce neuronal death and dysfunction, ensure the normal work of proteins, and achieve the effect of slowing disease progression.

.

▲Many mechanisms that lead to neurodegenerative diseases are related to endoplasmic reticulum and mitochondrial dysfunction (picture source: Amylyx's official website) A phase 2/3 trial published in September last year proved that AMX0035 can effectively slow the progression of ALS
.

Relevant trial data have been published in "New England Journal of Medicine" and Muscle and Nerve
.

Amylyx will continue to cooperate with the US FDA to initiate phase 3 clinical trials of AMX0035 in ALS patients
.

In addition, in June of this year, Amylyx has submitted a new drug application for AMX0035 for the treatment of ALS to Health Canada
.

And it plans to submit a marketing authorization application (MAA) for AMX0035 to the European Medicines Agency (EMA) Committee for Medicines for Human Use (CHMP) at the end of this year
.

"Amylyx has a clear mission: to develop new therapies for the treatment of ALS and other progressive neurodegenerative diseases
.

" Mr.
James Frates, Chief Financial Officer of Amylyx, said, "We are implementing the plan step by step, and we very much hope to bring AMX0035 to ALS as soon as possible.
Patients, alleviate their pain
.

"Reference: [1] Amylyx Pharmaceuticals Closes $135M Series C Financing Led by Viking Global Investors to Support Late Stage Development of Lead Product Candidate AMX0035 for the Treatment of ALS.
Retrieved July 20, 2021, from https:// .
com/news/home/20210720005268/en/Amylyx-Pharmaceuticals-Closes-135M-Series-C-Financing-Led-by-Viking-Global-Investors-to-Support-Late-Stage-Development-of-Lead-Product -Candidate-AMX0035-for-the-Treatment-of-ALS[2] Amylyx raises $135M to gear up for potential Canadian launch of ALS drug.
Retrieved July 20, 2021, from https:// /amylyx-raises-135m-as-it-gears-up-for-potential-canada-launch-als-drug Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation
.

If you need treatment plan guidance, please Go to a regular hospital for treatment
.